Bruker Corp

  • Industrials
  • Biotechnology: Laboratory Analytical Instruments
  • www.bruker.com
  • Earnings Score
  • Moat Score
  • Safety Score
  • Market Cap $5.89K
  • PE 0
  • Debt $2.13B
  • Cash $186.70M
  • EV $1.94B
  • FCF $136.00M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings$113.10M
EBIT$253.10M
ROE6%
ROA4%
FCF$136.00M
Equity$1.80B
Growth Stability34%
PE0
PEG0
PB0
P/FCF0
P/S0
Price/Cash31.72K
Debt/Equity1.18
Debt/FCF15.64
Net Margins3%
Gross Margins49%
Op. Margins8%
Earnings CAGR14%
Sales Growth YoY15%
Sales Growth QoQ13%
Sales CAGR9%
FCF CAGR4%
Equity CAGR9%
Earnings Stability0.55
Earnings Growth YoY-93%
Earnings Growth QoQ-67%
Earnings CAGR 5Y12%
Sales CAGR 5Y12%
FCF CAGR 5Y-4%
Equity CAGR 5Y15%
Earnings CAGR 3Y13%
Sales CAGR 3Y13%
FCF CAGR 3Y7%
Equity CAGR 3Y28%
Market Cap$5.89K
Revenue$3.37B
Dividend Yield513K%
Payout Ratio27%
Assets$5.81B
Total Debt$2.13B
Cash$186.70M
Shares Outstanding149
EV1.94B
Earnings Score80%
Moat Score65%
Safety Score44%
Final Score63%
Working Capital771.9M
Current Ratio1.6
Gross Profit$1.65B
Shares Growth 3y-0%
Equity Growth QoQ-2%
Equity Growth YoY29%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker BioSpin Group, Bruker Calid Group, Bruker Scientific Instruments Nano, and Bruker Energy & Supercon Technologies. The Bruker BioSpin Group and Bruker Calid Group are aggregated into BSI Life Science segment for reporting purposes, and it provides the highest revenue stream to the firm. The largest proportion of Bruker's revenue comes from Europe, though the firm also has a significant presence in the United States and Asia. It has its major technical and manufacturing centers in Europe, North America, Southeast Asia, as well as sales offices throughout the world.

SEC Filings

Direct access to Bruker Corp (BRKR) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Bruker Corp compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Bruker Corp compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 14%
Stability 55%
loading chart...

Bruker Corp Discounted Cash Flow

Fully customizable DCF calculator online for Bruker Corp.

= $1.8B
012345678910TV
fcf$136M$142M$148M$155M$162M$169M$177M$185M$193M$201M$210M$2.1B
DCF$129M$123M$116M$111M$105M$100M$95M$90M$85M$81M$811M
Value$1.8B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Net Margins6%10%4%9%10%8%11%12%14%3%3%
ROA-10%11%12%11%8%11%12%13%4%4%
ROE-22%11%20%22%16%26%26%31%6%6%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Debt over FCF-4.613.751.895.83.67.68.535.7715.6415.64
Debt over Equity0.360.620.570.40.890.871.331.11.011.181.18
Growth Stability---100%100%100%100%100%100%34%34%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024CAGR 5Y
Revenue YoY growth--1%10%7%9%-4%22%5%17%14%12%
Earnings YoY growth-51%-49%129%10%-20%76%7%44%-74%12%
Equity YoY growth--5%6%23%1%6%11%4%24%29%15%
FCF YoY growth--52%18%72%-26%67%-19%-24%67%-44%-4%